CatalystFDA/Bio

$TGTX

- PHASE 1 RESULTS OF SUBCUTANEOUS BRIUMVI ARE A DE-RISKING EVENT

TGTX

$53.93

-3.21%

What changed

- PHASE 1 RESULTS OF SUBCUTANEOUS BRIUMVI ARE A DE-RISKING EVENT

Why it matters

Phase 1 subcutaneous Briumvi results are a de-risking event for TG Therapeutics.

Sources